Renal fibrosis

Frontiers in Bioscience

Volumn 8, Issue , 2003, Pages

  Schnaper, H William ^a   Kopp, Jeffrey B ^b  

^a Pediatrics W 140   (United States)

^b NONE

Author keywords

Fibrosis; Glomerulosclerosis; Interstitial Fibrosis; Kidney; Progressive Kidney Disease; Review

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANGIOTENSIN ANTAGONIST; ANTIOXIDANT; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIN; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; GLUCOSE; GROWTH HORMONE; INSULIN; LEPTIN; METHYLXANTHINE DERIVATIVE; OSTEOGENIC PROTEIN 1; OSTEOPONTIN; PENTOSAN POLYSULFATE; PIRFENIDONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; PROTEOGLYCAN; REACTIVE OXYGEN METABOLITE; RELAXIN; SCATTER FACTOR; SOMATOMEDIN; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

CELL DIFFERENTIATION; CELL INTERACTION; EXTRACELLULAR MATRIX; FIBROGENESIS; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; HUMAN; KIDNEY; KIDNEY FIBROSIS; NONHUMAN; PATHOPHYSIOLOGY; REVIEW;

GLOMERULUS;

EID: 3142778623     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: None     Document Type: Review

References (195)

1. Eddy AA: Molecular basis of renal fibrosis. Pediatr Nephrol 15:290-301 (2000)
2. Harris DC: Tubulointerstitial renal disease. Curr Opin Nehprol Hypertens 10:315-320 (2001)
3. Zeisberg M, F Strutz & GA Muller: Renal fibrosis: an update. Curr Opin Nephrol Hypertens 10:315-320 (2001)
4. Waller JR & ML Nicholson: Molecular mechanisms of renal allograft fibrosis. Br J Surg 88:1429-1441 (2001)
5. Kriz W & KV Lemley: The role of the podocyte in glomerulosclerosis. Curr Opin Nephrol Hypertens 8:489-497 (1999)
6. Schwartz MM: The role of podocyte injury in the pathogenesis of focal segmental glomerulosclerosis. Ren Fail 22:663-684 (2000)
7. Fogo AB: Mesangial matrix modulation and glomerulosclerosis. Exp Nephrol 7:147-159 (1999)
8. van Kooten C, MR Daha & LA van Es: Tubular epithelial cells: A critical cell type in the regulation of renal inflammatory processes. Exp Nephrol 7:429-437 (1999)
9. Grupp C & GA Muller: Renal fibroblast culture. Exp Nephrol 7:377-385 (1999)
10. Schnaper HW: Focal segmental glomerulosclerosis. In: Immunologic Renal Disease, 2nd edition, Eds: Neilson EG & Couser WG, Lippincott Williams and Willkins, Philadelphia, 1001-1027 (2001)
11. Ruggenenti P, A Perna, L Mosconi, R Pisoni & G Remuzzi: Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int. 53:1209-1216 (1998)
12. Schnaper HW & AM Robson: Nephrotic syndrome: minimal change disease, focal glomerulosclerosis, and related disorders. In: Diseases of the Kidney and Urinary Tract, 7th Edition, Eds: Schrier RW & Gottschalk CW, Lippincott Williams & Wilkins, Philadelphia, 1773-1831 (2001)
13. Glicklich D, L Haskell, D Senitzer & RA Weiss: Possible genetic predisposition to idiopathic focal segmental glomerulosclerosis. Am. J. Kid. Dis. 12:26-30 (1988)
14. Lenhard V, DE Muller-Wiefel, J Dippell, D Schroder, S Seidel & K Scharer: HLA in minimal change nephrotic syndrome and focal segmental glomerulosclerosis. Pediatr. Res. 14:1003A (1980)
15. Tejani A, A Nicastri, K Phadke, D Sen, O Adamson, I Dunn & P Calderon: Familial focal segmental glomerulosclerosis. Int. J. Pediatr. Nephrol. 4:231-234 (1983)
16. Ruder H, K Scharer, G Opelz, V Lenhard, R Waldherr, DE Muller-Wiefel, A-M Wingen & J Dippell: Human leukocyte antigens in idiopathic nephrotic syndrome in children. Pediatr. Nephrol. 4:478-481 (1990)
17. Haskell LP, D Glicklich & D Senitzer: HLA associations in heroin-associated nephropathy. Am. J. Kid. Dis. 12:45-50 (1988)
18. Noel LH, B Descamps, P Jungers, JF Bach, M Busson, C Suet, J Hors & J Dausset: HLA antigens in three types of glomerulonephritis. Clin. Immunol. Immunopathol. 10:19-23 (1983)
19. Freedman BI, BJ Spray & ER Heise: HLA associations in IgA nephropathy and focal and segmental glomerulosclerosis. Am. J. Kid. Dis. 23:352-357 (1994)
20. Komori K, Y Nose, H Inouye, K Tsuji, Y Nomoto, Y Tomino, H Sakai, H Iwagaki, H Itoh & O Hasegawa: Immunogenetical study in patients with chronic glomerulonephritis. Tokai J. Exp. Clin. Med. 8:135-148 (1983)
21. Ingulli E & A Tejani: Racial differences in the incidence and renal outcome of idiopathic focal segmental glomerulosclerosis in children. Pediatr. Nephrol. 5:393-397 (1991)
22. Pettit DJ, MF Saad, PH Bennett, RG Nelson & WC Knowler: Familial predisposition to renal disease in two generations of Pima Indians with type-2 (non-insulin dependent) diabetes mellitus. Diabetologia 33:438-443 (1990)
23. Patrakka J, M Kestila, J Wartiovaara, V Ruotsalainen, P Tissari, U Lenkkeri, M Mannikko, V I., C Holmberg, J Rapola, K Tryggvason & H Jalanko: Congenital nephrotic syndrome (NPHS1): features resulting from different mutations in Finnish patients. Kidney Int. 58:972-980 (2000)
24. Boute N, O Gribouval, S Roselli, F Benessy, H Lee, A Fuchshuber, K Dahan, M-C Gubler, P Niaudet & C Antignac: NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nature Genetics 24:349-354 (2000)
25. Kaplan JM, S-H Kim, KN North, H Rennke, LA Correia, H-Q Tong, BJ Mathis, J-C Rodriguez-Perez, PG Allen, AH Beggs & MR Pollak: Mutations in ACTN4, encoding α-actinin-4, cause familial focal segmental glomerulosclerosis. Natire Genetics 24:251-256 (2000)
26. Denamur E, N Bocquet, B Mougenot, F Da Silva, L Martinat, C Loirat, J Elion, A Bensman & PM Ronco: Mother-to-child transmitted WT1 splice-site mutation is responsible for distinct glomerular disease. J. Am. Soc. Nephrol. 10:2219-2223 (1999)
27. Wehrmann M, A Bohle, H Held, G Schumm, H Kendziorra & H Pressler: Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin. Nephrol. 33:115-122 (1990)
28. Southwest Pediatric Nephrology Study Group: Focal segmental glomerulosclerosis in children with idiopathic nephrotic syndrome in children. A report of the Southwest Pediatric Nephrology Study Group. Kidney Int. 27:442-449 (1985)
29. Raij L, S Azar & WF Keane: Role of hypertension in progressive glomerular immune injury. Hypertension 7:398-404 (1985)
30. Raij L, S Azar & W Keane: Mesangial immune injury, hypertension and progressive glomerular damage in Dahl rats. Kidney Int. 26:137-143 (1984)
31. Elema JD & A Arends: Focal and segmental glomerular hyalinosis and sclerosis in the rat. Lab. Invest. 33:554-561 (1975)
32. Simons JL, AP Provoost, S Anderson, JL Troy, HG Rennke, DJ Sandstrom & BM Brenner: Pathogenesis of glomerular injury in the fawn-hooded rat: early glomerular capilalry hypertension predicts glomerular sclerosis. J. Am. Soc. Nephrol. 3:1775-1782 (1993)
33. Kamanna VS & MA Kirschenbaum: Association between very-low-density lipoprotein and glomerular injury in obese Zucker rats. Am. J. Nephrol. 13:53-58 (1993)
34. Makino H, Y Yamasaki, K Hironaka & Z Ota: Glomerular extracellular matrices in rat diabetic glomerulopathy by scanning electron microscopy. Virchows Archiv B, Cell Pathol. Mol. Pathol. 62:19-24 (1992)
35. Han JS & K Doi: Morphometric study on the renal glomeruli of streptozotocin (SZ)-induced diabetic APA hamsters. Histol. Histopathol. 7:549-554 (1992)
36. Tolins JP, BG Stone & L Raij: Interactions of hypercholesterolemia and hypertension in initiation of glomerular injury. Kidney Int. 41:1254-1261 (1992)
37. Al-Shebeb T, J Frohlich & AB Magil: Glomerular disease in hypercholesterolemic guinea pigs: a pathogenetic study. Kidney Int. 33:498-507 (1988)
38. Roy LP, RL Vernier & AF Michael: Effect of protein-load proteinuria on glomerular polyanion. Proc. Soc. Exp. Biol. Med. 141:870-874 (1972)
39. Olson JL, TH Hostetter, HG Rennke, BM Brenner & MA Venkatachalam: Altered glomerular permselectivity and progressive sclerosis following extreme ablation of renal mass. Kidney Int. 22:112-126 (1982)
40. Bagchus WM, MF Jeunink & JD Elema: The mesangium in anti-Thy1 nephritis. Influx of macrophages, mesangial cell hypercellularity, and macromolecular accumulation. Am. J. Pathol. 137:215-223 (1990)
41. Glasser RJ, JA Velosa & AF Michael: Experimental model of focal sclerosis. I. Relationship to protein excretion in aminonucleoside nephrosis. Lab. Invest. 36:519-526 (1977)
42. Chevalier RL, BA Thornhill & AY Chang: Unilateral ureteral obstruction in neonatal rats leads to renal insufficiency in adulthood. Kidney Int 58:1987-1995 (2000)
43. Guo G, J Morrissey, R McCracken, T Tolley, H Liapis & S Klahr: Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis. Am. J. Physiol. - Renal Fluid & Elect. 280:F777-F785 (2001)
44. Doi T, LJ Striker, C Quaife, FG Conti, R Palmiter, R Behringer, R Brinster & GE Striker: Progressive glomerulosclerosis develops in transgenic mice expressing growth hormone and growth hormone releasing factor but not in those expressing insulinlike growth factor-1. Am. J. Pathol. 131:398-403 (1988)
45. Suematsu S, T Matsuda, K Aozasa, S Akira, N Nakano, S Ohno, J-I Miyazaki, T Hirano & T Kishimoto: IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc. Natl. Acad. Sci., USA 86:7547-7551 (1989)
46. Stein PL, H Vogel & P Soriano: Combined deficiencies of Src, Fyn, and Yes tyrosine kinases in mutant mice. Genes Devel 8:1997-2007 (1994)
47. Kopp JB, VM Factor, M Mozes, P Nagy, N Sanderson, EP Bottinger, PE Klotman & SS Thorgeirsson: Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 74:991-1003 (1996)
48. Zwacka RM, A Reuter, E Pfaff, J Moll, K Gorgas, M Karasawa & H Weiher: The glomerulosclerosis gene Mpv17 encodes a peroxisomal protein producing reactive oxygen species. EMBO J. 13:5129-5134 (1994)
49. Velosa JA, VE Torres, JV Donadio, RD Wagoner, KE Holley & KP Offord: Treatment of severe nephrotic syndrome with meclofenamate: An uncontrolled pilot study. Mayo Clin. Proc. 60:586-592 (1985)
50. Bank N, R Klose, HS Aynedjian, D Nguyen & LB Sablay: Evidence against increased glomerular pressure initiating diabetic nephropathy. Kidney Int. 31:898-905 (1987)
51. Anderson S, TW Meyer, HG Rennke & BM Brenner: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76:612-619 (1985)
52. Riser BL, P Cortes & J Yee: Modelling the effects of vascular stress in mesangial cells. Curr Opin Nephrol Hypertens 9:43-47 (2000)
53. Fogo A, EP Hawkins, PL Berry, AD Glick, ML Chiang, RC MacDonnell & I Ichikawa: Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis. Kidney Int. 38:115-123 (1990)
54. Yoshida Y, A Fogo & I Ichikawa: Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int. 35:654-660 (1989)
55. Ikoma M, T Yoshioka, I Ichikawa & A Fogo: Mechanism of the unique susceptibility of deep cortical glomeruli of maturing kidneys to severe focal glomerular sclerosis. Pediat. Res. 28:270-276 (1990)
56. Avram MM: Similarities between glomerular sclerosis and atherosclerosis in human renal biopsy specimens: a role for lipoprotein glomerulopathy. Am. J. Med. 87:5.39N-35.43N (1989)
57. Schlondorff D: Cellular mechanisms of lipid injury in the glomerulus. Am. J. Kidney Dis. 22:72-82 (1993)
58. Hirano T & T Morohoshi: Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis. Nephron 60:443-447 (1992)
59. Schmitz PG, MP O'Donnell, BL Kasiske, SA Katz & WF Keane: Renal injury in obese Zucker rats: glomerular hemodynamic alterations and effects of enalapril. Am. J. Physiol. 263:F496-F502 (1992)
60. Kees-Folts D, JL Sadow & GF Schreiner: Tubular catabolism of albumin is associated with the release of an inflammatory lipid. Kidney Int. 45:1697-1709 (1994)
61. Diamond JR: Effects of dietary interventions on glomerular pathophysiology. Am. J. Physiol. 258:F1-F8 (1990)
62. Eddy AA: Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J. Am. Soc. Nephrol. 5:1273-1287 (1994)
63. Kriz W, H Hosser, B Hahnel, N Gretz & AP Provoost: From segmental glomerulosclerosis to total nephron degeneration and interstitial fibrosis: a histopathological study in rat models and human glomerulopathies. Nephrol Dial Transplant 13:2781-2798 (1998)
64. Oikawa T, M Freeman, W Lo, DE Vaughan & A Fogo: Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 51:164-172 (1997)
65. Schnaper HW: Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis. Pediatr. Nephrol. 9:104-111 (1995)
66. Hansen K & CK Abrass: Role of laminin isoforms in glomerular structure. Pathobiology 67:84-91 (1999)
67. Jones CL, S Buch, M Post, L McCulloch, E Liu & AA Eddy: Pathogenesis of interstitial fibrosis in chronic purine aminonucleoside nephrosis. Kidney Int. 40:1020-1031 (1991)
68. Sternlicht MD & Z Werb: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463-516 (2001)
69. Lijnen HR: Elements of the fibrinolytic system. Ann N Y Acad Sci 936:226-236 (2001)
70. Liotta LA, RH Goldfarb & VP Terranova: Cleavage of laminin by thrombin and plasmin: alpha thrombin selectively cleaves the beta chain of laminin. Thrombosis Res. 21:663-673 (1981)
71. Baricos WH, SL Cortez, SS El-Dahr & HW Schnaper: ECM degradation by cultured human mesangial cells is mediated by a plasminogen activator/plasmin/ matrix metalloproteinase 2 cascade. Kidney Int. 47:1039-1047 (1995)
72. Harendza S, AS Pollock & DH Lovett: The 5′ regulatory region of the rat 72 kDa type IV collagenase gene contains a strong mesangial-specific enhancer. J. Am. Soc. Nephrol. 3:653 (1993)
73. Reckelhoff JF & C Bayliss: Glomerular metalloprotease activity in the aging rat kidney: inverse correlation with injury. J. Am. Soc. Nephrol. 3:1835-1838 (1993)
74. Davies M, J Martin, GT Thomas & DH Lovett: Proteinases and glomerular matrix turnover. Kidney Int. 41:671-678 (1992)
75. Eddy AA, H Kim, J Lopez-Guisa, T Oda & PD Soloway: Interstitial fibrosis in mice with overload proteinuria: deficiency of TIMP-1 is not protective. Kidney Int. 58:618-628 (2000)
76. Rerolle J-P, A Hertig, G Nguyen, J-D Sraer & EP Rondeau: Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int. 58:1841-1850 (2000)
77. Mar PK, P Roy, HL Yin, HD Cavanagh & JV Jester: Stress fiber formation is required for matrix reorganization in a corneal myofibroblast cell line. Exp Eye Res 72:455-466 (2001)
78. Kaplan JM, SH Kim, KN North, H Rennke, LA Correia, HQ Tong, BJ Mathis, JC Rodriguez-Perez, PG Allen, AH Beggs & MR Pollak: Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 24:251-256 (2000)
79. Kambham N, N Tanji, RL Seigle, GS Markowitz, L Pulkkinen, J Uitto & VD D'Agati: Congenital focal segmental glomerulosclerosis associated with beta4 integrin mutation and epidermolysis bullosa. Am J Kidney Dis 36:190-196 (2000)
80. Haseley LA, C Hugo, MA Reidy & RJ Johnson: Dissociation of mesangial cell migration and proliferation in experimental glomerulonephritis. Kidney Int. 56:964-972 (1999)
81. Gilbert RE, DJ Kelly, T McKay, S Chadban, PA Hill, ME Cooper, RC Atkins & DJ Nikolic-Paterson: PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int. 59:1324-1332 (2001)
82. Muller E, A Burger-Kentischer, W Neuhofer, ML Fraek, J Marz, K Thurau & FX Beck: Possible involvement of heat shock protein 25 in the angiotensin II-induced glomerular mesangial cell contraction via p38 MAP kinase. J Cell Physiol 181:462-469 (1999)
83. Ohta K, S Kim, A Hamaguchi, T Yukimura, K Miura, K Takaori & H Iwao: Role of angiotensin II in extracellular matrix and transforming growth factor-beta 1 expression in hypertensive rats. Eur. J. Pharmacol. 269:115-119 (1994)
84. Poncelet A-C & HW Schnaper: Regulation of mesangial cell collagen turnover by transforming growth factor-β1. Am. J. Physiol. 275 (Renal Physiol. 44):F458-F466 (1998)
85. Tomooka S, WA Border, BC Marshall & NA Noble: Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int. 42:1462-1469 (1992)
86. Fumo P, GS Kuncio & FN Ziyadeh: PKC and high glucose stimulate collagen α1(IV) transcriptional activity in a reporter meangial cell line. Am. J. Physiol. 267:F632-F638 (1994)
87. Poncelet A-C, MP de Caestecker & HW Schnaper: The TGF-β/SMAD signaling pathway is present and functional in human mesangial cells. Kidney Int. 56:1354-1365 (1999)
88. Bhandari BK, D Feliers, S Duraisamy, JL Stewart, AC Gingras, HE Abboud, GG Choudhury, N Sonenberg & BS Kasinath: Insulin regulation of protein translation repressor 4E-BP1, and eIF4E-binding protein, in renal epithelial cells. Kidney int. 59:866-875 (2001)
89. Yang J & Y Liu: Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am. J. Pathol. 159:1465-1475 (2002)
90. Iehara N, H Takeoka, H Ysuji, T Imabayashi, DN Foster, AR Strauch, Y Yamada, T Kita & T Doi: Differentiation of smooth muscle phenotypes in mouse mesangial cells. Kidney Int 49:1330-1341 (1996)
91. Eddy A: Role of cellular infiltrates in response to proteinuria. Am J Kidney Dis 37(Suppl 2):S25-29 (2001)
92. Yasuda T, S Kondo, T Homma & RC Harris: Regulation of extracellular matrix by mechanical stress in rat glomerular mesangial cells. J Clin Invest 98:1991-2000 (1996)
93. Hara M, T Yanagihara & I Kihara: Urinary podocytes in primary focal segmental glomerulosclerosis. Nephron 89:342-347 (2001)
94. Branton MH & JB Kopp: TGF-beta and fibrosis. Microbes Infect 1:1349-1365 (1999)
95. Hayashida T, A-C Poncelet, SC Hubchak & HW Schnaper: TGF-b1 activates MAP kinases in human mesangial cells: a possible role in collagen expression. Kidney Int. 56:1710-1720 (1999)
96. Gupta S, MR Clarkson, J Duggan & HR Brady: Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 58:1389-1399 (2000)
97. Clarkson MR, S Gupta, M Murphy, F Martin, C Godson & HR Brady: Connective tissue growth factor: a potential stimulus for glomerulosclerosis and tubulointerstitial fibrosis in progressive renal disease. Curr Opin Nephrol Hypertens 8:543-548 (1999)
98. Riser BL, M Denichilo, P Cortes, C Baker, JM Grondin, J Yee & RG Narins: Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11:25-38 (2000)
99. Frazier KS, A Paredes, P Dube & E Styer: Connective tissue growth factor expression in the rat remnant kidney model and association with tubular epithelial cells undergoing transdifferentiation. Vet Pathol 37:328-335 (2000)
100. Williams B: Angiotensin II and the pathophysiology of cardiovascular remodeling. Am J Cardiol 87:10C-17C (2001)
101. Mezzano SA, M Ruiz-Ortega & J Egido: Angiotensin II and renal fibrosis. Hypertension 38:635-638 (2001)
102. Fogo AB: New insights into the renin-angiotensin system and hypertensive renal disease. Curr Hypertens Rep 1:187-194 (1999)
103. Border WA & N Noble: Maximizing hemodynamic-independent effects of angiotensin II antagonists in fibrotic diseases. Semin Nephrol 21:563-572 (2001)
104. Cao Z & ME Cooper: Role of angiotensin II in tubulointerstitial injury. Semin Nephrol 21:554-562 (2001)
105. Ma L & AB Fogo: Role of angiotensin II in glomerular injury. Semin Nephrol 21:544-553 (2001)
106. Anderson PW, XY Zhang, J Tian, JD Correale, XP Xi, D Yang, K Graf, RE Law & WA Hsueh: Insulin and angiotensin II are additive in stimulating TGF-β and matrix mRNAs in mesangial cells. Kidney Int. 50:745-753 (1996)
107. Doi T, LJ Striker, CC Gibson, LY Agodoa, RL Brinster & GE Striker: Glomerular lesions in mice transgenic for growth hormone and insulinlike growth factor-I. I. Relationship between increased glomerular size and mesangial sclerosis. Am J Pathol 137:541-552 (1990)
108. Hirschberg R: Bioactivity of glomerular ultrafiltrate during heavy proteinuria may contribute to renal tubulointerstitial lesions: evidence for a role for insulin-like growth factor I. J Clin Invest 98:116-124 (1996)
109. Doublier S, D Seurin, B Fouqueray, MC Verpont, P Callard, LJ Striker, GE Striler, M Binoux & L Baud: Glomerulosclerosis in mice transgenic for human insulin-like growth factor-binding protein-1. Kidney Int. 57:2299-2307 (2000)
110. Feld S & R Hirschberg: Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev 17:423-480 (1996)
111. Segev Y, D Landau, R Rasch, A Flyvbjerg & M Phillip: Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice. J Am Soc Nephrol 10:2374-2381 (1999)
112. Floege J, W Kriz, M Schulze, M Susani, D Kerjaschki, A Mooney, WG Couser & KM Koch: Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. J Clin Invest 96:2809-2819 (1995)
113. Terzi F, M Burtin, M Hekmati, P Federici, G Grimber, P Briand & G Friedlander: Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulointerstitial lesions after renal injury. J Clin Invest 106:225-234 (2000)
114. Chevalier RL, S Goyal & BA Thornhill: EGF improves recovery following relief of unilateral ureteral obstruction in the neonatal rat. J. Urol. 162:1532-1536 (1999)
115. Benigni A, C Zola, D Corna, S Orisio, D Facchinetti, L Benati & G Remuzzi: Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am J Kidney Dis 27:416-423 (1996)
116. Hocher B, C Thone-Reineke, P Rohmeiss, F Schmager, T Slowinski, V Burst, F Siegmund, T Quertermous, C Bauer, HH Neumayer, WD Schleuning & F Theuring: Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 99:1380-1389 (1997)
117. Guo G, J Morrissey, R McCracken, T Tolley & S Klahr: Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol 277:F766-772 (1999)
118. O'Regan A & JS Berman: Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 81:373-390 (2000)
119. Ophascharoensuk V, JW Pippin, KL Gordon, SJ Shankland, WG Couser & RJ Johnson: Role of intrinsic renal cells versus infiltrating cells in glomerular crescent formation. Kidney Int 54:416-425 (1998)
120. Ophascharoensuk V, CM Giachelli, K Gordon, J Hughes, R Pichler, P Brown, L Liaw, R Schmidt, SJ Shankland, CE Alpers, WG Couser & RJ Johnson: Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 56:571-580 (1999)
121. Wolf G, A Hamann, DC Han, U Helmchen, F Thaiss, FN Ziyadeh & RA Stahl: Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int 56:860-872 (1999)
122. Wolf G, S Chen, DC Han & FN Ziyadeh: Leptin and renal disease. Am J Kidney Dis 39:1-11 (2002)
123. Bassuk JA, R Pichler, JD Rothmier, J Pippen, K Gordon, RL Meek, AD Bradshaw, D Lombardi, TP Strandjord, M Reed, EH Sage, WG Couser & R Johnson: Induction of TGF-beta1 by the matricellular protein SPARC in a rat model of glomerulonephritis. Kidney Int 57:117-128 (2000)
124. Francki A & EH Sage: SPARC and the kidney glomerulus: matricellular proteins exhibit diverse functions under normal and pathological conditions. Trends Cardiovasc Med 11:32-37 (2001)
125. Trojanowska M: Ets factors and regulation of the extracellular matrix. Oncogene 19:6464-6471 (2000)
126. Ziyadeh FN, ER Snipes, M Watanabe, RJ Alvarez, S Goldfarb & TP Haverty: High glucose induces cell hypertrophy and stimulates collagen gene transcription in proximal tubule. Am. J. Physiol. 259:F704-F714 (1990)
127. Murphy M, C Godson, S Cannon, S Kato, HS Mackenzie, F Martin & HR Brady: Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 274:5830-5834 (1999)
128. Heidland A, K Sebekova & R Schinzel: Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 38:S100-106 (2001)
129. Yang CW, H Vlassara, EP Peten, CJ He, GE Striker & LJ Striker: Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 91:9436-9440 (1994)
130. Twigg SM, MM Chen, AH Joly, SD Chakrapani, J Tsubaki, HS Kim, Y Oh & RG Rosenfeld: Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 142:1760-1769 (2001)
131. Vlassara H, LJ Striker, S Teichberg, H Fuh, YM Li & M Steffes: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 91:11704-11708 (1994)
132. Mott JD, RG Khalifah, H Nagase, CF Shield, JK Hudson & BG Hudson: Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int. 52 (1997)
133. Yamamoto Y, I Kato, T Doi, H Yonekura, S Ohashi, M Takeuchi, T Watanabe, S Yamagishi, S Sakurai, S Takasawa, H Okamoto & H Yamamoto: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108:261-268 (2001)
134. Geiszt M, JB Kopp, P Varnai & TL Leto: Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci U S A 97:8010-8014 (2000)
135. Leonarduzzi G, A Sevanian, B Sottero, MC Arkan, F Biasi, E Chiarpotto, H Basaga & G Poli: Up-regulation of the fibrogenic cytokine TGF-beta1 by oxysterols: a mechanistic link between cholesterol and atherosclerosis. Faseb J 15:1619-1621 (2001)
136. Moriyama T, N Kawada, K Nagatoya, M Horio, E Imai & M Hori: Oxidative stress in tubulointerstitial injury: therapeutic potential of antioxidants towards interstitial fibrosis. Nephrol Dial Transplant 15 Suppl 6:47-49 (2000)
137. Norman JT, C Orphanides, P Garcia & LG Fine: Hypoxia-induced changes in extracellular matrix metabolism in renal cells. Exp Nephrol 7:463-469 (1999)
138. Epstein M: Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives. Intern Med 40:573-583 (2001)
139. Imai E & Y Isaka: Targeting growth factors to the kidney: myth or reality? Curr Opin Nephrol Hypertens 11:49-57 (2002)
140. Coker RK & GJ Laurent: Pulmonary fibrosis: cytokines in the balance. Eur Respir J 11:1218-1221 (1998)
141. Ulloa L, J Doody & J Massague: Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 397:710-713 (1999)
142. Strutz F, M Heeg, T Kochsiek, G Siemers, M Zeisberg & GA Muller: Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts. Nephrol Dial Transplant 15:1535-1546 (2000)
143. Oldroyd SD, GL Thomas, G Gabbiani & AM El Nahas: Interferon-gamma inhibits experimental renal fibrosis. Kidney Int 56:2116-2127 (1999)
144. Ziesche R, E Hofbauer, K Wittmann, V Petkov & LH Block: A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 341:1264-1269 (1999)
145. Kopp JB: Hepatocyte growth factor: mesenchymal signal for epithelial homeostasis. Kidney Int 54:1392-1393 (1998)
146. Matsumoto K & T Nakamura: Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 59:2023-2038 (2001)
147. Yang J & Y Liu: Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 13:96-107 (2002)
148. Mizuno S, T Kurosawa, K Matsumoto, Y Mizuno-Horikawa, M Okamoto & T Nakamura: Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J Clin Invest 101:1827-1834 (1998)
149. Dai C, J Yang & Y Liu: Single injection of naked plasmid encoding hepatocyte growth factor prevents cell death and ameliorates acute renal failure in mice. J Am Soc Nephrol 13:411-422 (2002)
150. Takayama H, WJ LaRochelle, SG Sabnis, T Otsuka & G Merlino: Renal tubular hyperplasia, polycystic disease, and glomerulosclerosis in transgenic mice overexpressing hepatocyte growth factor/scatter factor. Lab Invest 77:131-138 (1997)
151. Lund RJ, MR Davies & KA Hruska: Bone morphogenetic protein-7: an anti-fibrotic morphogenetic protein with therapeutic importance in renal disease. Curr Opin Nephrol Hypertens 11:31-36 (2002)
152. Hruska KA, G Guo, M Wozniak, D Martin, S Miller, H Liapis, K Loveday, S Klahr, TK Sampath & J Morrissey: Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol Renal Physiol 279:F130-143 (2000)
153. Morrissey J, K Hruska, G Guo, S Wang, Q Chen & S Klahr: Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol 13 Suppl 1:S14-21 (2002)
154. Unemori EN, LB Pickford, AL Salles, CE Piercy, BH Grove, ME Erikson & EP Amento: Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 98:2739-2745 (1996)
155. Williams EJ, RC Benyon, N Trim, R Hadwin, BH Grove, MJ Arthur, EN Unemori & JP Iredale: Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut 49:577-583 (2001)
156. Garber SL, Y Mirochnik, CS Brecklin, EN Unemori, AK Singh, L Slobodskoy, BH Grove, JA Arruda & G Dunea: Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int 59:876-882 (2001)
157. Kang DH, J Hughes, M Mazzali, GF Schreiner & RJ Johnson: Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 12:1448-1457 (2001)
158. Border WA, NA Noble, T Yamamoto, JR Harper, Y Yamaguchi, MD Pierschbacher & E Ruoslahti: Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360:361-364 (1992)
159. Isaka Y, DK Brees, K Ikegaya, Y Kaneda, E Imai, NA Noble & WA Border: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 2:418-423 (1996)
160. Linz W & BA Scholkens: A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 105:771-772 (1992)
161. Ma LJ, S Nakamura, JS Whitsitt, C Marcantoni, JM Davidson & AB Fogo: Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 58:2425-2436 (2000)
162. Brown NJ, S Nakamura, L Ma, I Nakamura, E Donnert, M Freeman, DE Vaughan & AB Fogo: Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58:1219-1227 (2000)
163. Lewis EJ, LG Hunsicker, WR Clarke, T Berl, MA Pohl, JB Lewis, E Ritz, RC Atkins, R Rohde & I Raz: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860 (2001)
164. Parving HH, H Lehnert, J Brochner-Mortensen, R Gomis, S Andersen & P Arner: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878 (2001)
165. Gurujeyalakshmi G, MA Hollinger & SN Giri: Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 276:L311-318 (1999)
166. Cain WC, RW Stuart, DL Lefkowitz, JD Starnes, S Margolin & SS Lefkowitz: Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol 20:685-695 (1998)
167. Kaneko M, H Inoue, R Nakazawa, N Azuma, M Suzuki, S Yamauchi, SB Margolin, K Tsubota & I Saito: Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin Exp Immunol 113:72-76 (1998)
168. Misra HP & C Rabideau: Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem 204:119-126 (2000)
169. Shimizu T, M Fukagawa, T Kuroda, S Hata, Y Iwasaki, M Nemoto, K Shirai, S Yamauchi, SB Margolin, F Shimizu & K Kurokawa: Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl 63:S239-243 (1997)
170. Shimizu T, T Kuroda, S Hata, M Fukagawa, SB Margolin & K Kurokawa: Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 54:99-109 (1998)
171. Bobadilla NA, I Tack, E Tapia, LG Sanchez-Lozada, J Santamaria, F Jimenez, LJ Striker, GE Striker & J Herrera-Acosta: Pentosan polysulfate prevents glomerular hypertension and structural injury despite persisting hypertension in 5/6 nephrectomy rats. J Am Soc Nephrol 12:2080-2087 (2001)
172. Ma LJ, C Marcantoni, MF Linton, S Fazio & AB Fogo: Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 59:1899-1910 (2001)
173. Bhat VB & KM Madyastha: Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline. Biochem Biophys Res Commun 288:1212-1217 (2001)
174. Tsai TJ, RH Lin, CC Chang, YM Chen, CF Chen, FN Ko & CM Teng: Vasodilator agents modulate rat glomerular mesangial cell growth and collagen synthesis. Nephron 70:91-99 (1995)
175. Chen YM, CT Chien, MI Hu-Tsai, KD Wu, CC Tsai, MS Wu& TJ Tsai: Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int 56:932-943 (1999)
176. Ducloux D, C Bresson-Vautrin & J Chalopin: Use of pentoxifylline in membranous nephropathy. Lancet 357:1672-1673 (2001)
177. Guerrero-Romero F, M Rodriguez-Moran, JR Paniagua-Sierra, G Garcia-Bulnes, M Salas-Ramirez & D Amato: Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. Clin Nephrol 43:116-121 (1995)
178. Van den Branden C, R Verelst, J Vamecq, K Vanden Houte & D Verbeelen: Effect of vitamin E on antioxidant enzymes, lipid peroxidation products and glomerulosclerosis in the rat remnant kidney. Nephron 76:77-81 (1997)
179. Nankervis A, K Nicholls, G Kilmartin, P Allen, S Ratnaike & FI Martin: Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study. Metabolism 47:12-15 (1998)
180. Rudberg S, R Osterby, HJ Bangstad, G Dahlquist & B Persson: Effect of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with Type I (insulin-dependent) diabetes mellitus. Diabetologia 42:589-595 (1999)
181. Cordonnier DJ, N Pinel, C Barro, M Maynard, P Zaoui, S Halimi, BH de Ligny, Y Reznic, D Simon & RW Bilous: Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group. J Am Soc Nephrol 10:1253-1263 (1999)
182. Drukker A & AA Eddy: Failure of antioxidant therapy to attenuate interstitial disease in rats with reversible nephrotic syndrome. J Am Soc Nephrol 9:243-251 (1998)
183. Hu D, MA Hughes & GW Cherry: Topical tamoxifen-a potential therapeutic regime in treating excessive dermal scarring? Br J Plast Surg 51:462-469 (1998)
184. Chau D, JS Mancoll, S Lee, J Zhao, LG Phillips, GK Gittes & MT Longaker: Tamoxifen downregulates TGF-beta production in keloid fibroblasts. Ann Plast Surg 40:490-493 (1998)
185. Neugarten J, A Acharya, J Lei & S Silbiger: Selective estrogen receptor modulators suppress mesangial cell collagen synthesis. Am J Physiol Renal Physiol 279:F309-318 (2000)
186. Zdunek M, S Silbiger, J Lei & J Neugarten: Protein kinase CK2 mediates TGF-β1-stimulated type IV collagen gene transcription and its reversal by estradiol. Kidney Int. 60:2097-2108 (2001)
187. Potier M, SJ Elliot, I Tack, O Lenz, GE Striker, LJ Striker & M Karl: Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9. J. Am. Soc. Nephrol. 12(2):241-251 (2001)
188. Neugarten J, A Acharya & S Silbiger: Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J. Am. Soc. Nephrol. 11:319-329 (2000)
189. Kagan HM: Intra- and extracellular enzymes of collagen biosynthesis as biological and chemical targets in the control of fibrosis. Acta Trop 77:147-152 (2000)
190. Elliot SJ, LJ Striker, WG Stetler-Stevenson, TA Jacot & GE Striker: Pentosan polysulfate decreases proliferation and net extracellular matrix production in mouse mesangial cells. J Am Soc Nephrol 10:62-68 (1999)
191. Nwogu JI, D Geenen, M Bean, MC Brenner, X Huang & PM Buttrick: Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation 104:2216-2221 (2001)
192. Bickel M, KH Baringhaus, M Gerl, V Gunzler, J Kanta, L Schmidts, M Stapf, G Tschank, K Weidmann & U Werner: Selective inhibition of hepatic collagen accumulation in experimental liver fibrosis in rats by a new prolyl 4-hydroxylase inhibitor. Hepatology 28:404-411 (1998)
193. Matsumura Y, I Sakaida, K Uchida, T Kimura, T Ishihara & K Okita: Prolyl 4-hydroxylase inhibitor (HOE 077) inhibits pig serum-induced rat liver fibrosis by preventing stellate cell activation. J Hepatol 27:185-192 (1997)
194. Fioretto P, MW Steffes, DE Sutherland, FC Goetz & M Mauer: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339:69-75 (1998)
195. GISEN: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349:1857-1863 (1997)